Tyra Current Deferred Revenue from 2010 to 2026
| TYRA Stock | USD 32.34 1.52 4.93% |
Current Deferred Revenue | First Reported 2010-12-31 | Previous Quarter 327.6 K | Current Value 291.2 K | Quarterly Volatility 19.2 K |
Check Tyra Biosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Tyra Biosciences' main balance sheet or income statement drivers, such as Net Interest Income of 21.4 M, Depreciation And Amortization of 626.7 K or Interest Expense of 357.4 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 2.19. Tyra financial statements analysis is a perfect complement when working with Tyra Biosciences Valuation or Volatility modules.
Tyra | Current Deferred Revenue | Build AI portfolio with Tyra Stock |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Tyra Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Tyra Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Tyra Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Tyra Biosciences Stock:Check out the analysis of Tyra Biosciences Correlation against competitors. For information on how to trade Tyra Stock refer to our How to Trade Tyra Stock guide.You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tyra Biosciences. If investors know Tyra will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Tyra Biosciences assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Understanding Tyra Biosciences requires distinguishing between market price and book value, where the latter reflects Tyra's accounting equity. The concept of intrinsic value—what Tyra Biosciences' is actually worth based on fundamentals—guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Tyra Biosciences' price substantially above or below its fundamental value.
Please note, there is a significant difference between Tyra Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Tyra Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Tyra Biosciences' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.